

Regionalization of Cancer Care

Conflicts of Interest




















Ontario begins dismantling local health integration system

ELIZABETH PAYNE Updated: March 15, 2019



Kitchener-Waterloo

Reconsider public health restructuring, regional councillors tell province

(f) 🔰 🖾 🍯 (in)


Province needs to hear 'this is not an improvement,' regional chair says Kirthana Sasitharan - CBC News - Posted: Aug 13, 2019 4:08 PM ET | Last Updated: August 13



The region's community services committee passed a motion Tuesday to send a report to the province with concerns about the implications of the restructuring public health boards in Ontario. (Kirthana Sasitharan/CBC)



Ontario to lay off more than 400 people at health agencies as government continues cutting jobs



Health Services Research Queen's Cancer Research Institute

Population-based data

- Ontario Cancer Registry
- Hospital discharge data
- Statistics Canada
- Regional cancer center clinical databases
- ICES

1990-2013

- 81,566 prostate cancer
- 6,145 bladder cancer
- 533 penile cancer



Overview Regionalization/Bladder Cancer

- Houston, we have a problem
 - Apollo 13 (1995)
- What are you talkin' about Willis?
 - Gary Coleman (1978)
- The bureaucrats are in charge now. What options have we?
 - Star Wars: The Phantom Menace (1999)



The NEW ENGLAND JOURNAL of MEDICINE

SPECIAL ARTICLE

The Quality of Health Care Delivered to Adults

in the United States

VOLUME 34 · NUMBER 8 · MARCH 10, 2016

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

ADULT UROLOGY



CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER: PATTERNS AND OUTCOMES OF CARE IN THE MEDICARE POPULATION

DEBORAH SCHRAG, NANDITA MITRA, FENG XU, FARHANG RABBANI, PETER B. BACH, HARRY HERR, AND COLIN B. BEGG Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer

Matthew D. Galsky, Kristian D. Stensland, Erin Moshier, John P. Sfakianos, Russell B. McBride, Che-Kai Tsao, Martin Casey, Paolo Boffetta, William K. Oh, Madhu Mazumdar, and Juan P. Wisnivesky

Original article

Annals of Oncology 14 (Supplement 5): v61-v118, 2003 DOI: 10.1093/annonc/mdg754

EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary

M. Sant¹*‡¶, T. Aareleid²‡, F. Berrino¹‡¶, M. Bielska Lasota³‡, P. M. Carli⁴‡, J. Faivre⁵‡, P. Grosclaude⁶‡, G. Hédelin⁷‡, T. Matsuda⁶‡, H. Møller⁸‡, T. Möller⁹‡, A. Verdecchia¹⁰‡¶, R. Capocaccia¹⁰¶, G. Gatta¹¶, A. Micheli¹¶, M. Santaquilani¹⁰¶, P. Roazzi¹⁰¶, D. Lisi¹⁰¶ and the EUROCARE Working Group[†]

Effect of Preoperative Delay on Survival in Patients With Bladder Cancer Undergoing Cystectomy in Quebec: A Population Based Study

Salaheddin M. Mahmud, Brian Fong, Nader Fahmy, Simon Tanguay and Armen G. Aprikian*,†

From the Departments of Oncology (SMM), Surgery (Urology) (SMM, BF, NF, ST, AGA) and Epidemiology and Biostatistics (SMM), McGill University, Montreal, Quebec, Canada

Ontario Context-Access to Care/Delayed Diagnosis?

- 8005 deaths from bladder cancer
- Cystectomy 2409 (30%)
- Radiation 737 (9%)
- None 4859 (61%)
- 25% (n=1,964) received palliative chemotherapy
 - Geographic variation from 18% to 30%

Ontario Context-Early Outcomes-Cystectomy

Post-operative mortality rates


- Tertiary Care Centres:
 - 30, 90-days were 1.3% and 3.2%
- Quebec:
 - 30, 90 days were 2.8% and 7.5%
- Ontario:
 - 30, 90 days were 2.5% and 8.7%

Zakaria, CUAJ, 2014 Siemens, Urology 2014 Yafi, BJUI, 2011

Ontario Context-MIBC Survival

Among all cases in Ontario

- 5 yr OS 30% (95% CI 28-31%)
- 5 yr CSS 34% (95% CI 32-36%)









Today's Daily Briefing View the Archives Print Today's Stories

Inside the fierce debate over surgical volume standards

Experts speak out for—and against—the 'volume pledge'



69.2% less than 5/year



42.6% less than 10/year

Effect of Hospital and Surgeon Volume

Hospital Volume

Surgeon	Vo	lume
---------	----	------

	Q1 <4.1 cases/yr N=763	Q2 4.1-8.2 cases/yr	Q3 8.3-20.0 cases/yr	Q4 >20.0 cases/yr
	11-705	N=730	N=648	N=661
Median/Mean LOS	16/13 days	16/12 days	16/11 days	13/9 days
Post-operative mortality				
30-day mortality rate	26 (3%)	20 (3%)	15 (2%)	10 (2%)
90-day mortality	76 (10%)	77 (11%)	47 (7%)	44 (7%)
date				
Post-operative				
morbidity#				
30-day readmission	104 (14%)	85 (12%)	111 (17%)	124 (19%)
rate				
90-day readmission	236 (31%)	200 (27%)	206 (32%)	254 (38%)
rate				
5 year OS (95%CI)	27% (24-31%)	28% (25-32%)	29% (26-32%)	35% (31-
				38%)
5 year CSS (95%CI)	31% (28-36%)	32% (28-36%)	35% (30-38%)	38% (33-
				42%)

	Q1 <1.3 cases/yr N=705	Q2 1.3-2.4 cases/yr N=797	Q3 2.5-6.2 cases/yr N=676	Q4 >6.2 cases/yr N=624
Mean/Median LOS	17/12	16/12	15/11	13/10
Post-operative mortality				
30-day mortality rate	22 (3%)	23 (3%)	16 (2%)	10 (2%)
90-day mortality	79 (11%)	69 (9%)	56 (8%)	40 (6%)
date				
Post-operative morbidity [#]				
30-day readmission	223 (32%)	216 (27%)	201 (30%)	256 (41%)
rate				
90-day readmission	93 (13%)	91 (11%)	97 (14%)	143 (23%)
rate				
5 year OS (95%CI)	28%	28%	27%	36%
5 year CSS (95%CI)	31%	33%	33%	39%

Decreased LOS

Lower post-operative mortality Higher readmission rates Better 5 year OS/CSS

Siemens, Urology 2014

Regionalization

Deliberate reorganization of cancer services based on explicit and planned processes and structures, with the intent of improving the quality of care

Consolidation


The merger and/or acquisition of smaller health organizations into larger ones


The purpose of consolidation is not an increase in quality of care, but rather an increase in efficiency

Passive Centralization

Reorganized care delivery through a process of unintentional consolidation of care to specific sites

Based on natural geographic location of hospitals in relation to population density or may reflect the choices of referring clinicians or patients





Regionalization = Volume Effect

Institute of Medicine recommended tracking case volumes for major cancer surgeries as a quality indicator

Large consortia groups of health care purchasers began to support selective referral to high-volume centers and surgeons

Extensive regionalization of complex cancer surgery over the past 10 years

Push back

Yearly experience vs lifetime experience?

Low volume surgeons in high volume centers?

Unintended consequencesinappropriate procedures to "make my numbers"?

Cross-training-do similar cases count? Training the next generation? Patient preference and autonomy? Where does it end?



Arguments against a simplistic structure-focused (provider volume) case for regionalization

Limitations of Volume-Outcome Literature

Databases of restricted populations

- Lack information on important prognostic factors, (stage, co-morbidity)
- Procedure-specific risk adjustment tool
- Few address long-term survival
- Adjust for the relative effects of both surgeon and hospital volume
- Investigate process-of-care factors underpinning the volume-outcome relationship

Furthermore

- 1. Patient willingness and ability to travel for cancer care
- 2. Marginalize rural populations already experiencing disparities in access to care and outcomes
- 3. Higher-volume center has the necessary resources to provide care in a timely manner
- 4. Further reduction of case volume/expertise at low-volume centers
- 5. Requirement for increased involvement of and coordination with primary care providers
- 6. Benefits from implemented regionalization policies for complex surgeries have not been uniformly demonstrated

Is provider volume an appropriate surrogate measure for improved outcomes?

Quality of Care Framework

Structure

- Characteristics such as professionals, equipment, resources

Process


 Care that is provided and the technical or inter-personal aspects of the delivery of the care

Outcomes

 states of health or events that are consequences of the care provided to patients

		SURGEON Volume				
	Q1 (low	Q2	Q3	Q4 (high		
	volume)			volume)		
Pre-op MO referral^	102 (23%)	122 (30%)	121 (27%)	116 (29%)	0.141	
Pre-op MO referral*	95 (28%)	112 (34%)	104 (31%)	99 (35%)	0.224	
Pre-op RO referral^	44 (10%)	50 (12%)	93 (21%)	46 (11%)	<0.001	
PLND yes^	396 (90%)	364 (89%)	430 (97%)	398 (99%)	<0.001	
Median node count#					< 0.001	
(IQR)	9 (5-15)	10 (6-15)	11 (7-18)	15 (9-21)		
Mean node density	0.34 ± 0.27	0.31 ± 0.25	0.28 ± 0.26	0.26 ± 0.25	0.096	
Margin status					0.685	
Any positive	83 (19%)	71 (17%)	89 (20%)	71 (18%)		
All negative	349 (79%)	331 (81%)	351 (79%)	330 (82%)		
Unstated	7 (2%)	6 (1%)	<=5 (1%)	<=5 (1%)		
NACT rate*	56 (16%)	63 (19%)	52 (15%)	72 (25%)	0.009	
ACT rate*	60 (17%)	77 (23%)	63 (19%)	55 (19%)	0.283	

Quality Indicators PLND



LND, number, and density are strongly associated with hospital/surgeon volume

Siemens et al Urol Oncol 2015

Explanatory Variables of Cystectomy Volume Effect

	QUARTILE		VARIABLES ADDED TO THE MODEL					
		Volume alone	Volume +	Volume +	Volume+	Volume+		
			#no de s *	#no de s∧	nodes*/ACT/margin	nodes^/ACT/margin		
OS	Q1	1.28 (1.07-1.53)	1.23 (1.02-1.47)	1.23 (1.02-1.48)	1.21 (1.01-1.45)	1.21 (1.01-1.46)		
	Q2	1.31 (1.10-1.55)	1.25 (1.04-1.49)	1.25 (1.05-1.49)	1.23 (1.03-1.46)	1.23 (1.03-1.47)		
	Q3	1.30 (1.10-1.54)	1.26 (1.07-1.50)	1.27 (1.07-1.51)	1.26 (1.06-1.50)	1.27 (1.08-1.51)		
	Q4	REF	REF	REF	REF	REF		
CSS	Q1	1.29 (1.06-1.58)	1.25 (1.02-1.54)	1.22 (0.99-1.50)	1.25 (1.01-1.53)	1.22 (0.99-1.50)		
	Q2	1.22 (1.01-1.49)	1.18 (0.96-1.45)	1.15 (0.94-1.41)	1.17 (0.96-1.44)	1.15 (0.94-1.41)		
	Q3	1.23 (1.02-1.49)	1.21 (0.99-1.47)	1.20 (0.99-1.45)	1.22 (1.00-1.48)	1.21 (1.00-1.47)		
	Q4	REF	REF	REF	REF	REF		

Node dissection explains some of the difference seen in CSS across quartiles

Quality Indicators Pre-operative Imaging

Characteristic	Overall Surviv	Overall Survival			Cancer Specific Survival	
	5 year OS	Multivariate analysis		5 year CSS	Multivariate ana	ysis
	_	HR (95%CI)	P trend		HR (95%CI)	P trend
				,		
Chest imaging			0.035			0.151
Yes (n=2129)	31%	Ref		35%	Ref	
No (n=669)	26%	1.12 (1.01-1.24)		31%	1.09 (0.97-1.22)	

Characteristic	Overall Surv	ival	Cancer Specific Survival			
	5 year OS	Multivariate analysis		5 year CSS	Multivariate analysis	
		HR (95%CI)	Ptrend		HR (95%CI) P tre	nd
				1		
Bone scan			0.032		0.03	0
Yes (n=949)	31%	Ref		36%	Ref	
No (n=1849)	28%	1.11 (1.01-1.22)		32%	1.13 (1.01-1.25)	

Quality Indicators Peri-operative Care

Anesthesiology Volumes ≅ Readmission Rates




Jaeger, Anes Anal, 2016

Quality Indicators Transfusion

	RBC Tr	p-value	
	Yes	No	
	N=1608	N=985	
Outcome			
Mean LOS (days)	17	11	< 0.001
Median LOS (days)	11	9	< 0.001
30 day mortality	60 (4%)	15 (2%)	0.001
90 day mortality	171 (11%)	43 (4%)	< 0.001
30 day re-admission [#]	448 (28%)	181 (18%)	< 0.001
90 day re-admission [#]	615 (38%)	284 (29%)	< 0.001
5 year OS (95% CI)	32% (29-34%)	47% (44-50%)	< 0.001
5 year CSS (95% CI)	38% (36-41%)	54% (50-57%)	< 0.001


Wait times (unadjusted) and cause-specific survival



Shorter wait times ≈ 1/cause-specific survival

Siemens, 2005 Siemens, 2005

Follow-up Care



More follow-up care≈ 1/cause-specific survival

Chan, Int J Cancer, 2008


Benchmarking Quality Indicators

- Expert opinion/"evidence based"
- The University of Alabama at Birmingham's Achievable Benchmarks of Care (ABC[™]s)
 - peer-group based, data driven method for identifying benchmark performance for a variety of process-of-care indicators.
 - achieved by calculating a "pared-mean", defined as the mean of the best care achieved for at least 10% of the population
- Criterion-based benchmarking (CBB)
 - empirical method for estimating the appropriate rate of the use of a specific therapy that does not require comprehensive information about case mix at the population level

NACT Benchmarks

Significant systematic variation in perioperative CT rates across hospitals (0-52%)


The benchmark rates was 36-41%




My Thoughts

- Modest "centralization" to avoid low volume providers is strongly supported
- Regionalization of urological oncology in Ontario will be complex and potentially problematic
- Focus on improving processes of care optimal (benchmarking)


Passive Centralization in Ontario



Centralization associated with NACT/ACT



Centralization associated with 90-day mortality



Year of cystectomy

Centralization associated with improved survival

